| [1] |
Sun W, Shen ZY, Zhang H, et al. Overexpression of HIF-1α in primary gallbladder carcinoma and its relation to vasculogenic mimicry and unfavourable prognosis[J]. Oncol Rep, 2012, 27(6):1990-2002.
|
| [2] |
Pais-Costa SR, Farah JF, Artigiani-Neto R, et al. Evaluation of P53, E-cadherin, Cox-2, and EGFR protein immunoexpression on prognostic of resected gallbladder carcinoma[J]. Arq Bras Cir Dig, 2014, 27(2):126-132.
|
| [3] |
Won HS, Lee MA, Chung ES, et al. Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer[J]. BMC Cancer, 2010 (10):564.
|
| [4] |
Suzuki H, Roa JC, Kawamoto T, et al. Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients[J]. Mol Clin Oncol, 2015, 3(3):464-470.
|
| [5] |
Letelier P, Garcia P, Leal P, et al. Immunohistochemical expression of vascular endothelial growth factor A in advanced gallbladder carcinoma[J]. Appl Immunohistochem Mol Morphol, 2014, 22(7):530-536.
|
| [6] |
Li CF, Fang FM, Wang JM, et al. EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact[J]. Ann Surg Oncol, 2012, 19(2):443-454.
|
| [7] |
Yang L, Guo T, Jiang S, et al. Expression of ezrin, HGF and c-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder[J]. Hepatogastroenterology, 2012, 59(118):1769-1775.
|
| [8] |
Sun XN, Cao WG, Wang X, et al. Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma[J]. Tumour Biol, 2011, 32(6):1183-1190.
|
| [9] |
Lin W, Jiang L, Chen Y, et al. Vascular endothelial growth factor-D promotes growth, lymphangiogenesis and lymphatic metastasis in gallbladder cancer[J]. Cancer Lett, 2012, 314(2):127-136.
|
| [10] |
Chen Y, Jiang L, She F, et al. Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism[J]. Mol Cell Biochem, 2010, 345(1/2):77-89.
|
| [11] |
Yang Z, Yang Z, Xiong L, et al. Expression of VHL and HIF-1α and their clinicopathologic significance in benign and malignant lesions of the gallbladder[J]. Appl Immunohistochem Mol Morphol, 2011, 19(6):534-539.
|
| [12] |
Batmunkh E, Shimada M, Morine Y, et al. Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma[J]. Int J Clin Oncol, 2010, 15(1):59-64.
|
| [13] |
Legan M. Cyclooxygenase-2, p53 and glucose transporter-1 as predictors of malignancy in the development of gallbladder carcinomas[J]. Bosn J Basic Med Sci, 2010, 10(3):192-196.
|
| [14] |
Doval DC, Azam S, Sinha R, et al. Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: association with clinicopathological profiles and outcomes in gallbladder carcinoma[J]. J Carcinog, 2014 (13):10.
|
| [15] |
Qiu Y, Luo X, Kan T, et al. TGF-β upregulates miR-182 expression to promote gallbladder cancer metastasis by targeting CADM1[J]. Mol Biosyst, 2014, 10(3):679-685.
|
| [16] |
Riley E, Carloss H. Dramatic response to panitumumab and bevacizumab in metastatic gallbladder carcinoma[J]. Oncologist, 2011, 16(5):e1-2.
|
| [17] |
Moehler M, Maderer A, Schimanski C, et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme[J]. Eur J Cancer, 2014, 50(18):3125-3135.
|